Psychiatric diagnosis

Caravel Autism Health Welcomes New Board Member

Retrieved on: 
Thursday, July 22, 2021
Psychiatric diagnosis, Psychiatry, Autism, Branches of biology, Caravel, Medical specialties

CHICAGO, July 22, 2021 /PRNewswire/ -- Caravel Autism Health announced today the expansion of its board of directors with the addition of Michelle Wright.

Key Points: 
  • CHICAGO, July 22, 2021 /PRNewswire/ -- Caravel Autism Health announced today the expansion of its board of directors with the addition of Michelle Wright.
  • Caravel has focused on targeted industry experience as well as increasing board diversity and adding a parent's perspective.
  • "We are pleased to welcome Michelle as our board's newest member," said Mike Miller, Chief Executive Officer for Caravel.
  • Since 2009, Caravel Autism Health has been devoted to helping families navigate the challenges of childhood autism.

Alector to Present New Data from Frontotemporal Dementia and Alzheimer’s Disease Programs at the 2021 Alzheimer’s Association International Conference

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Psychiatry, Cognitive disorders, Psychiatric diagnosis, Neuroscience, Granulin, Dementia, Frontal lobe, Frontotemporal dementia, Infront Sports & Media, Alector

SOUTH SAN FRANCISCO, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the upcoming 2021 Alzheimer’s Association International Conference being held July 26-30, 2021 virtually and in Denver, Colorado.

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the upcoming 2021 Alzheimers Association International Conference being held July 26-30, 2021 virtually and in Denver, Colorado.
  • Among the data being presented at the conference will be six- and twelve-month data from the open-label Phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN).
  • Alector plans to host a conference call to review the AL001 Phase 2 results on July 29 at 1:00 p.m.
  • Alector will also present two posters related to its AL002 Alzheimers disease (AD) program.

KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.

Retrieved on: 
Wednesday, July 21, 2021
Psychiatry, Amphetamine, Childhood psychiatric disorders, Methylphenidate, Psychiatric diagnosis, Abnormal psychology, Neuroscience, Attention deficit hyperactivity disorder

The U.S. commercial launch of AZSTARYS is a significant milestone for KemPharm and an important advancement in the treatment of ADHD, a disease indication that has seen little innovation in recent years, said Travis C. Mickle, Ph.D., President and CEO of KemPharm.

Key Points: 
  • The U.S. commercial launch of AZSTARYS is a significant milestone for KemPharm and an important advancement in the treatment of ADHD, a disease indication that has seen little innovation in recent years, said Travis C. Mickle, Ph.D., President and CEO of KemPharm.
  • Since the FDAs approval of AZSTARYS in March, the various teams across Corium have been working diligently to ready AZSTARYS for its U.S. launch.
  • We believe Corium has built a best-in-class commercial organization, and as a result, we expect the market potential for AZSTARYS will be maximized.
  • AZSTARYS is an FDA-approved, once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years or older.

ZOLL Medical Receives FDA Clearance for TBI Dashboard on Its Propaq M Monitor and Propaq MD Monitor/Defibrillator

Retrieved on: 
Wednesday, July 21, 2021
Technology, Other Defense, Contracts, Software, Hardware, Health, General Health, Data management, Defense, Neurotrauma, Medical specialties, Clinical medicine, Medicine, Medical emergencies, Intensive care medicine, Psychiatric diagnosis, Traumatic brain injury, TBI, ZOLL Medical Corporation, Asahi Kasei, ZOLL MEDICAL CORPORATION, ASAHI KASEI

ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has received FDA 510(k) clearance to release the TBI Dashboard feature on its Propaq M monitor and Propaq MD monitor/defibrillator.

Key Points: 
  • ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has received FDA 510(k) clearance to release the TBI Dashboard feature on its Propaq M monitor and Propaq MD monitor/defibrillator.
  • TBI Dashboard provides clinical decision support for managing patients with TBI (traumatic brain injury) and was previously available on Propaq devices in international markets.
  • From the point of injury throughout the continuum of en-route care, ZOLL's Propaq M and Propaq MD monitor/defibrillators, now with TBI Dashboard capabilities, support rapid treatment and effective management of TBI patients.
  • TBI Dashboard, X Series, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.

New Study Published in Nature Journal, Translational Psychiatry, by Taliaz, Presents New Approach for Predicting Response to Depression Treatment

Retrieved on: 
Wednesday, July 21, 2021
Major depressive disorder, Health sciences, Psychiatry, Branches of biology, Psychiatric diagnosis, STAR*D, Treatment of depression, Pharmacogenomics, Antidepressant, Treatment-resistant depression

"Current practice for MDD treatment relies mainly on trial and error, with an estimated 4253% response rates for antidepressant use.

Key Points: 
  • "Current practice for MDD treatment relies mainly on trial and error, with an estimated 4253% response rates for antidepressant use.
  • The authors analyzed response patterns of more than 4500 patients to antidepressant medications in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study and the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS).
  • "This peer-reviewed publication corroborates our unique approach for the design of the PREDICTIX prediction algorithm to optimize treatment for mental health.
  • The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis.

The Virginian Senior Living Community Launches Obie For Seniors Interactive Gaming System

Retrieved on: 
Wednesday, July 21, 2021
Psychiatry, Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Neuroscience, Dementia, Alzheimer's disease

Obie for Seniors is an award-winning interactive gaming system that projects onto any surface - tabletops, floors, and walls - encouraging active play through touching, moving, and hand-eye coordination skills.

Key Points: 
  • Obie for Seniors is an award-winning interactive gaming system that projects onto any surface - tabletops, floors, and walls - encouraging active play through touching, moving, and hand-eye coordination skills.
  • The system is among the newest "Nana" Technology being adopted for use in the United States for individuals with Alzheimer's and related dementia.
  • Based in Israel, EyeClick is a world leader in interactive technology for 15+ years and the creator of Obie for Seniors.
  • Obie helps to enhance the conditions of senior housing facilities, hospitals, and clinics with tailored interactive games that provide residents with engagement, fun, and encourages increased mobility and cognitive skills.

Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021

Retrieved on: 
Wednesday, July 21, 2021
Life sciences, Psychiatry, Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Biogen, Spinal muscular atrophy, Eisai, Dementia, Alzheimer's disease
Key Points: 
  • A poster presentation will also be given on the results of an in vivo study of E2511, Eisai's in-house discovered and developed investigational novel oral synapse regenerant.
  • Additionally, Eisai and Biogen Inc. (Nasdaq: BIIB) will hold a virtual symposium, "Defining the next-generation clinical care pathway for Alzheimer's disease: biological, technological, and healthcare perspectives," focusing on the AD treatment landscape.
  • Eisai serves as the lead in the co-development of lecanemab, an anti-Aβ protofibril antibody, which is being jointly developed by Eisai and Biogen.
  • Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia.

Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering

Retrieved on: 
Tuesday, July 20, 2021
Mental health, Health, Genetics, Other Science, Science, Pharmaceutical, Biotechnology, Branches of biology, Neuroscience, Psychiatry, Psychiatric diagnosis, Learning disabilities, Childhood psychiatric disorders, Autism, Educational psychology, Attention deficit hyperactivity disorder, Neurocognition, Cognitive disorder, Autism spectrum

Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”), today announced the closing of its initial public offering (the “Offering”) of 2,300,000 ordinary shares at a public offering price of $9.50 per share.

Key Points: 
  • Regencell Bioscience Holdings Limited (NASDAQ:RGC) (Regencell or the Company), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), today announced the closing of its initial public offering (the Offering) of 2,300,000 ordinary shares at a public offering price of $9.50 per share.
  • The Company received aggregate gross proceeds of $21.9 million from the Offering, before deducting underwriting discounts and other related expenses.
  • Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on research, development and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD.
  • All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the Companys proposed Offering.

Nobu: A Mental Health App that Provides Everything You Need to Explore Your Thoughts, Emotions and Mental Health Goals.

Retrieved on: 
Tuesday, July 20, 2021
Psychiatry, Self, Mind, Mental health, Abnormal psychology, Psychiatric diagnosis, Positive psychology, Social constructionism, Mental disorder, Recovery model, Health, Services for mental disorders

In the wake of the COVID-19 pandemic, the need for mental health resources became even more urgent.

Key Points: 
  • In the wake of the COVID-19 pandemic, the need for mental health resources became even more urgent.
  • Left untreated, mental health symptoms can negatively impact nearly all aspects of a person's life.
  • Nobu will help more people to get the help they need to take good care of their mental health, regardless of where they live.
  • Advanced Recovery Systems (ARS) is an integrated behavioral health care management company dedicated to the treatment of addiction, substance abuse and mental health conditions.

Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials

Retrieved on: 
Tuesday, July 20, 2021
Human sexuality, Penis, cGMP-specific phosphodiesterase type 5, Psychiatric diagnosis, Penis disorders, Human penis, PDE5 inhibitor, Erectile dysfunction, Discovery and development of phosphodiesterase 5 inhibitors

The grant, titled Development of microparticle-based topical treatments for treating erectile dysfunction [ED] in patients refractory to oral PDE5 inhibitors, was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (a division of the NIH).

Key Points: 
  • The grant, titled Development of microparticle-based topical treatments for treating erectile dysfunction [ED] in patients refractory to oral PDE5 inhibitors, was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (a division of the NIH).
  • In the U.S. alone, these two market segments represent an addressable market of over $2 billion per year.
  • Notably, the Z-pod technology has successfully harnessed the therapeutic potential of nitric oxide, one of the most powerfuland short-livedbiomolecules produced by our bodies.
  • For more details, please visit our website, www.zylotherapeutics.com , and follow us on Twitter ( @ZyloTherapies ).